Evidence map›Paper›PMID 29563746›Full record

ArticleIndian journal of surgical oncology2018

Metastatic Renal Cell Cancer-Systemic Therapy.

Amit Joshi, Arvind Sahu, Vanita Noronha, Vijay Patil, Kumar Prabhash

Abstract read
In one paragraph

Article in Indian journal of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amit JoshiDepartment of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
Arvind SahuDepartment of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
Vanita NoronhaDepartment of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
Vijay PatilDepartment of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
Kumar PrabhashDepartment of Medical Oncology, Tata Memorial Hospital, Mumbai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Management of metastatic renal cell carcinoma (mRCC) has evolved considerably in the past 10 years due to better understanding of tumor biology. This development has changed mRCC to a chronic progressive disease with several lines of treatment options. The introduction of several new targeted therapies including immunotherapy has improved median overall survival of approximately 1 year to >2 years in mRCC.

Indexed as

Metastatic RCCPazopanibSunitinibTargeted therapy

Identifiers

PMID29563746
PMCPMC5856703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.